<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954471</url>
  </required_header>
  <id_info>
    <org_study_id>ML29903</org_study_id>
    <nct_id>NCT02954471</nct_id>
  </id_info>
  <brief_title>Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia</brief_title>
  <official_title>A Retrospective, Observational Molecular Epidemiology Study of HER2 Expression in Patients With Early / Metastatic Breast Cancer in Saudi Arabia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a retrospective, multicenter study, consisting of chart review of Saudi Arabian
      participants diagnosed with breast cancer between 2007 and 2013 and with available human
      epidermal growth factor receptor 2 (HER2) testing. Data on survival will be collected through
      2015.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Positive HER2 Test Result</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Estrogen Receptor/Progesterone Receptor Positive Breast Cancer</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Type of First-line and Subsequent Treatment Regimens Used</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of Overall Survival (OS)</measure>
    <time_frame>From January 2007 to December 2015 (Up to 9 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimates of Progression-free Survival (PFS) as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Response as Assessed Using RECIST</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Partial Response as Assessed Using RECIST</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Progressive Disease as Assessed Using RECIST</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Stable Disease as Assessed Using RECIST</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From January 2007 to December 2013 (Up to 7 years; assessed retrospectively)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">351</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Participants With Breast Cancer</arm_group_label>
    <description>This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants With Early/Metastatic Breast Cancer in Saudi Arabia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Initially diagnosed with breast cancer

          -  Has a proven result of HER2 testing by immunohistochemistry (IHC), fluorescent in situ
             hybridization (FISH) or any other in situ hybridization (ISH) method

          -  Alive or not alive

        Exclusion Criteria:

        - Inconclusive, equivocal or unavailable result of HER2/neu overexpression by IHC and FISH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML29903 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Fahad Specialist Hospital; Oncology</name>
      <address>
        <city>Dammam</city>
        <zip>31444</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Centre</name>
      <address>
        <city>Jeddah</city>
        <zip>21499</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Guard King Abdulaziz Medical City; Oncology</name>
      <address>
        <city>Riyadh</city>
        <zip>11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

